Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034136 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL183337 | 0.81 | CES1 (0.52) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL7030979 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL6929642 | 0.79 | CES1 (0.50) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL27825041 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL27419440 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL28794548 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL27901000 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL16634434 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL27969988 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1125056-C | Prepn. of 5-methyl-3-isooxazolyl methyl formate | KUNSHAN SHUANGHE PHARMACEUTICA (CN) | 2003-10-22 | — | — | CN | claimed |
| CN-1357544-A | Prepn. of 5-methyl-3-isooxazolyl methyl formate | KUNSHAN SHUANGHE PHARMACEUTICA (CN) | 2002-07-10 | — | — | CN | claimed |
| US-12378234-B2 | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative | BANTAM PHARMACEUTICAL, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | BANTAM PHARMACEUTICAL, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | disclosed |
| US-20220162204-A1 | CRYSTALLINE POLYMORPHS OF A 1-THIAZOL-2-YL-PYRAZOLE-5-CARBOXYLIC ACID DERIVATIVE | BANTAM PHARMACEUTICAL, LLC | 2022-05-26 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3976606-A1 | CRYSTALLINE POLYMORPHS OF A 1-THIAZOL-2-YL-PYRAZOLE-5-CARBOXYLIC ACID DERIVATIVE | Bantam Pharmaceutical, LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1125056-C | Prepn. of 5-methyl-3-isooxazolyl methyl formate | KUNSHAN SHUANGHE PHARMACEUTICA (CN) | 2003-10-22 | — | — | CN | disclosed |
| CN-1125056-C | Prepn. of 5-methyl-3-isooxazolyl methyl formate | KUNSHAN SHUANGHE PHARMACEUTICA (CN) | 2003-10-22 | — | — | CN | disclosed |
| CN-1357544-A | Prepn. of 5-methyl-3-isooxazolyl methyl formate | KUNSHAN SHUANGHE PHARMACEUTICA (CN) | 2002-07-10 | — | — | CN | disclosed |
| CN-1329654-A | Electroluminescent material | SOUTH BANK UNIV ENTPR LTD (GB) | 2002-01-02 | — | — | CN | disclosed |
| CN-1068316-C | Process for synthesizing 5-methyl-isoxazole-3-carboxamide | KUNSHAN GENERAL PHARMACEUTICAL (CN) | 2001-07-11 | — | — | CN | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | KRAS, TP53, CCNI | ALDH1A1 355/4885TSHR 3401/4885TDP1 1254/4885 |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | ALDH1A1 2041/4885TSHR 3660/4885TDP1 4230/4885 |
| US-11192887-B2 | — | KRAS, TP53, CCNE1 | ALDH1A1 207/4885TSHR 4066/4885TDP1 1393/4885 |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, NRAS | ALDH1A1 519/4885TSHR 3517/4885TDP1 1060/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | ALDH1A1 480/4885TSHR 2933/4885TDP1 1012/4885 |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | EIF4A1, EIF4A3, EIF4B | ALDH1A1 3399/4885TSHR 2807/4885TDP1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.